---
document_datetime: 2025-12-29 08:46:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/incruse-ellipta.html
document_name: incruse-ellipta.html
version: success
processing_time: 0.1180702
conversion_datetime: 2025-12-30 02:50:53.632478
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Incruse Ellipta (previously Incruse)

[RSS](/en/individual-human-medicine.xml/66314)

##### Authorised

This medicine is authorised for use in the European Union

umeclidinium bromide Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Incruse Ellipta (previously Incruse)](#news-on)
- [More information on Incruse Ellipta (previously Incruse)](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Incruse Ellipta is a medicine used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Incruse Ellipta is used for maintenance (regular) treatment.

Incruse Ellipta contains the active substance umeclidinium bromide.

Expand section

Collapse section

## How is Incruse Ellipta used?

Incruse Ellipta can only be obtained with a prescription. It is available as an inhalation powder in a portable inhaler device. Each inhalation provides 65 micrograms of umeclidinium bromide equivalent to 55 micrograms of umeclidinium.

The recommended dose is one inhalation per day at the same time each day. For detailed information on how to use the inhaler correctly, see the instructions in the package leaflet or contact your doctor or pharmacist.

## How does Incruse Ellipta work?

The active substance in Incruse Ellipta, umeclidinium bromide, is a muscarinic receptor antagonist. It works by blocking some receptors called muscarinic receptors, which control the contraction of muscles. When umeclidinium bromide is inhaled, it relaxes the muscles of the airways. This helps to keep the airways open and allows the patient to breathe more easily.

## What benefits of Incruse Ellipta have been shown in studies?

Incruse Ellipta was investigated in four main studies involving over 4,000 patients. Three studies compared Incruse Ellipta with placebo (a dummy treatment), while one study compared Incruse Ellipta with tiotropium (another medicine for COPD). The main measure of effectiveness was based on changes in the patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second).

Results showed that Incruse Ellipta improved lung function by an average FEV1 of 127 ml more than placebo after 12 weeks of treatment and by 115 ml more than placebo after 24 weeks of treatment. A double dose of Incruse Ellipta only showed small improvements compared with a single dose, which were not considered relevant. In the study comparing Incruse Ellipta with tiotropium, FEV1 improvements over 24 weeks were similar for both medicines.

The studies also showed an improvement in symptoms such as breathlessness and wheezing.

## What are the risks associated with Incruse Ellipta?

The most common side effects with Incruse Ellipta (which may affect up to 1 in 10 people) are headache, nasopharyngitis (inflammation of the nose and throat), upper respiratory tract infection (nose and throat infection), sinusitis (inflammation of the sinuses), cough, urinary tract infection (infection of the structures that carry urine), and tachycardia (increased heart rate).

For the full list of side effects and restrictions with Incruse Ellipta, see the package leaflet..

## Why is Incruse Ellipta authorised in the EU?

The European Medicines Agency decided that Incruse Ellipta's benefits are greater than its risks and it can be authorised for use in the EU. The Agency concluded that Incruse Ellipta was shown to be effective at improving lung function and symptoms of COPD. The Agency also noted that there were no major safety concerns with Incruse Ellipta, with side effects being manageable and similar to other medicines of the same class (antimuscarinic bronchodilators).

## What measures are being taken to ensure the safe and effective use of Incruse Ellipta?

As medicines of the same class as Incruse Ellipta may have an effect on the heart and blood vessels in the brain, the company that markets Incruse Ellipta will carry out a long-term study in patients to collect further information on its safety in comparison with tiotropium.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Incruse Ellipta have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Incruse Ellipta are continuously monitored. Side effects reported with Incruse Ellipta are carefully evaluated and any necessary action taken to protect patients.

## Other information about Incruse Ellipta

Incruse Ellipta received a marketing authorisation valid throughout the EU on 28 April 2014.

Incruse Ellipta : EPAR - Medicine overview

Reference Number: EMA/593792/2018

English (EN) (70.05 KB - PDF)

**First published:** 22/05/2014

**Last updated:** 16/10/2018

[View](/en/documents/overview/incruse-ellipta-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-359)

български (BG) (98.33 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/bg/documents/overview/incruse-ellipta-epar-medicine-overview_bg.pdf)

español (ES) (69.87 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/es/documents/overview/incruse-ellipta-epar-medicine-overview_es.pdf)

čeština (CS) (93.44 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/cs/documents/overview/incruse-ellipta-epar-medicine-overview_cs.pdf)

dansk (DA) (68 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/da/documents/overview/incruse-ellipta-epar-medicine-overview_da.pdf)

Deutsch (DE) (70.91 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/de/documents/overview/incruse-ellipta-epar-medicine-overview_de.pdf)

eesti keel (ET) (67.81 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/et/documents/overview/incruse-ellipta-epar-medicine-overview_et.pdf)

ελληνικά (EL) (105.33 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/el/documents/overview/incruse-ellipta-epar-medicine-overview_el.pdf)

français (FR) (71.18 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/fr/documents/overview/incruse-ellipta-epar-medicine-overview_fr.pdf)

hrvatski (HR) (88.07 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/hr/documents/overview/incruse-ellipta-epar-medicine-overview_hr.pdf)

italiano (IT) (69.22 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/it/documents/overview/incruse-ellipta-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (98.35 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/lv/documents/overview/incruse-ellipta-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (91.45 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/lt/documents/overview/incruse-ellipta-epar-medicine-overview_lt.pdf)

magyar (HU) (88.97 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/hu/documents/overview/incruse-ellipta-epar-medicine-overview_hu.pdf)

Malti (MT) (92.43 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/mt/documents/overview/incruse-ellipta-epar-medicine-overview_mt.pdf)

Nederlands (NL) (69.34 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/nl/documents/overview/incruse-ellipta-epar-medicine-overview_nl.pdf)

polski (PL) (94.81 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/pl/documents/overview/incruse-ellipta-epar-medicine-overview_pl.pdf)

português (PT) (70.07 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/pt/documents/overview/incruse-ellipta-epar-medicine-overview_pt.pdf)

română (RO) (98.46 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/ro/documents/overview/incruse-ellipta-epar-medicine-overview_ro.pdf)

slovenčina (SK) (93.03 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/sk/documents/overview/incruse-ellipta-epar-medicine-overview_sk.pdf)

slovenščina (SL) (86.32 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/sl/documents/overview/incruse-ellipta-epar-medicine-overview_sl.pdf)

Suomi (FI) (67.73 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/fi/documents/overview/incruse-ellipta-epar-medicine-overview_fi.pdf)

svenska (SV) (68.21 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/sv/documents/overview/incruse-ellipta-epar-medicine-overview_sv.pdf)

Incruse Ellipta : Risk management plan

English (EN) (865.15 KB - PDF)

**First published:** 18/01/2021

**Last updated:** 28/03/2025

[View](/en/documents/rmp/incruse-ellipta-risk-management-plan_en.pdf)

## Product information

Incruse Ellipta : EPAR - Product Information

English (EN) (630.73 KB - PDF)

**First published:** 22/05/2014

**Last updated:** 22/07/2025

[View](/en/documents/product-information/incruse-ellipta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-318)

български (BG) (691.66 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/bg/documents/product-information/incruse-ellipta-epar-product-information_bg.pdf)

español (ES) (563.52 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/es/documents/product-information/incruse-ellipta-epar-product-information_es.pdf)

čeština (CS) (653.64 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/cs/documents/product-information/incruse-ellipta-epar-product-information_cs.pdf)

dansk (DA) (582.12 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/da/documents/product-information/incruse-ellipta-epar-product-information_da.pdf)

Deutsch (DE) (607.75 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/de/documents/product-information/incruse-ellipta-epar-product-information_de.pdf)

eesti keel (ET) (520.25 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/et/documents/product-information/incruse-ellipta-epar-product-information_et.pdf)

ελληνικά (EL) (705.61 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/el/documents/product-information/incruse-ellipta-epar-product-information_el.pdf)

français (FR) (743.2 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/fr/documents/product-information/incruse-ellipta-epar-product-information_fr.pdf)

hrvatski (HR) (676.68 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/hr/documents/product-information/incruse-ellipta-epar-product-information_hr.pdf)

íslenska (IS) (509.53 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/is/documents/product-information/incruse-ellipta-epar-product-information_is.pdf)

italiano (IT) (716.44 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/it/documents/product-information/incruse-ellipta-epar-product-information_it.pdf)

latviešu valoda (LV) (628.5 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/lv/documents/product-information/incruse-ellipta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (685.01 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/lt/documents/product-information/incruse-ellipta-epar-product-information_lt.pdf)

magyar (HU) (754.32 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/hu/documents/product-information/incruse-ellipta-epar-product-information_hu.pdf)

Malti (MT) (759.34 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/mt/documents/product-information/incruse-ellipta-epar-product-information_mt.pdf)

Nederlands (NL) (573.1 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/nl/documents/product-information/incruse-ellipta-epar-product-information_nl.pdf)

norsk (NO) (506.29 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/no/documents/product-information/incruse-ellipta-epar-product-information_no.pdf)

polski (PL) (771.5 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/pl/documents/product-information/incruse-ellipta-epar-product-information_pl.pdf)

português (PT) (641.79 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/pt/documents/product-information/incruse-ellipta-epar-product-information_pt.pdf)

română (RO) (639.34 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/ro/documents/product-information/incruse-ellipta-epar-product-information_ro.pdf)

slovenčina (SK) (810.3 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/sk/documents/product-information/incruse-ellipta-epar-product-information_sk.pdf)

slovenščina (SL) (677.09 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/sl/documents/product-information/incruse-ellipta-epar-product-information_sl.pdf)

Suomi (FI) (581.34 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/fi/documents/product-information/incruse-ellipta-epar-product-information_fi.pdf)

svenska (SV) (589.26 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

22/07/2025

[View](/sv/documents/product-information/incruse-ellipta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** T/0000281876 17/07/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Incruse Ellipta : EPAR - All Authorised presentations

English (EN) (15.73 KB - PDF)

**First published:** 22/05/2014

**Last updated:** 16/10/2018

[View](/en/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-873)

български (BG) (44.13 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/bg/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_bg.pdf)

español (ES) (18.82 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/es/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (36.57 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/cs/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (9.27 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/da/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.83 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/de/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (46.9 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/et/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (39.42 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/el/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_el.pdf)

français (FR) (16.21 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/fr/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (49.39 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/hr/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (88.42 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/is/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (43.94 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/it/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.84 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/lv/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (49.26 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/lt/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.23 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/hu/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (49.5 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/mt/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (14.14 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/nl/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (16.22 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/no/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_no.pdf)

polski (PL) (49.28 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/pl/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_pl.pdf)

português (PT) (46.56 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/pt/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_pt.pdf)

română (RO) (48 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/ro/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (30.55 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/sk/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.64 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/sl/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (17.72 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/fi/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (13.81 KB - PDF)

**First published:**

22/05/2014

**Last updated:**

16/10/2018

[View](/sv/documents/all-authorised-presentations/incruse-ellipta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Incruse Ellipta (previously Incruse) Active substance umeclidinium bromide International non-proprietary name (INN) or common name umeclidinium bromide Therapeutic area (MeSH) Pulmonary Disease, Chronic Obstructive Anatomical therapeutic chemical (ATC) code R03BB07

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

## Authorisation details

EMA product number EMEA/H/C/002809 Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Opinion adopted 20/02/2014 Marketing authorisation issued 28/04/2014 Revision 22

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Incruse Ellipta : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (120.98 KB - PDF)

**First published:** 22/07/2025

[View](/en/documents/procedural-steps-after/incruse-ellipta-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Incruse Ellipta : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (225.24 KB - PDF)

**First published:** 13/02/2015

**Last updated:** 22/07/2025

[View](/en/documents/procedural-steps-after/incruse-ellipta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Incruse Ellipta-H-C-PSR-S-0048 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/565794/2024

English (EN) (143.75 KB - PDF)

**First published:** 12/12/2024

[View](/en/documents/scientific-conclusion/incruse-ellipta-h-c-psr-s-0048-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations_en.pdf)

Incruse Ellipta-H-C-PSUSA-00010263-202112 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Adopted

Reference Number: EMA/886127/2022

English (EN) (105.51 KB - PDF)

**First published:** 15/11/2022

[View](/en/documents/scientific-conclusion/incruse-ellipta-h-c-psusa-00010263-202112-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Incruse-H-C-PSUSA-10263-201812: EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/467304/2019

English (EN) (89.38 KB - PDF)

**First published:** 03/10/2019

[View](/en/documents/scientific-conclusion/incruse-h-c-psusa-10263-201812-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Incruse-H-C-PSUSA-00010263-201610 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/472868/2017

English (EN) (71.26 KB - PDF)

**First published:** 26/07/2017

**Last updated:** 26/07/2017

[View](/en/documents/scientific-conclusion/incruse-h-c-psusa-00010263-201610-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Incruse-H-C-PSUSA-10263-201604 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

English (EN) (77.09 KB - PDF)

**First published:** 20/01/2017

**Last updated:** 20/01/2017

[View](/en/documents/scientific-conclusion/incruse-h-c-psusa-10263-201604-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Incruse : EPAR - Public assessment report

Reference Number: EMA/175100/2014

English (EN) (4.36 MB - PDF)

**First published:** 22/05/2014

**Last updated:** 22/05/2014

[View](/en/documents/assessment-report/incruse-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Incruse

Adopted

Reference Number: EMA/CHMP/68182/2014

English (EN) (69.69 KB - PDF)

**First published:** 21/02/2014

**Last updated:** 21/02/2014

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-incruse_en.pdf)

#### News on Incruse Ellipta (previously Incruse)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 February 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-february-2014) 21/02/2014

#### More information on Incruse Ellipta (previously Incruse)

- [An open label, multi-centre, post marketing surveillance (PMS) to monitor the safety and efficacy of INCRUSE administered in Korean subjects with chronic obstructive pulmonary disease (COPD) in usual practice (205163) - post-authorisation study](https://catalogues.ema.europa.eu/study/40153)
- [Post-authorization safety Electronic Medical Records database retrospective cohort study of new users of inhaled UMEC/VI or new users of inhaled UMEC in the primary care setting - post-authorisation study](https://catalogues.ema.europa.eu/study/41147)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 22/07/2025

## Share this page

[Back to top](#main-content)